European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	69
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	64
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	56
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	56
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	48
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	42
Early initiation of SGLT2 inhibitors after acute myocardial infarction	38
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? . Why can't we see the evidence?	35
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	34
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	33
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	31
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	31
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	30
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	29
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	28
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle	27
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	27
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	27
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	26
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	24
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	23
All about clinical trials	23
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	22
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	22
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	22

Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	21
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	20
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	20
De-escalation versus shortening of dual antiplatelet therapy	19
New ways of mitigating aldosterone in cardiorenal disease	19
Late breaking clinical trials at ACC 22	19
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis	18
Cardiovascular prevention and risk factors	18
Long-term antiplatelet monotherapy after PCI: searching for the smart choice	18
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	18
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	18
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on one-year mortality in acute coronary syndrome patients	18
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial	17
News in cardiovascular pharmacotherapy from the ACC.24 Meeting	17
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease	17
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic	16
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!	16
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	15
Entering a new era of antiplatelet therapy: the 4D-ACS trial	15
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies	15
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial	15
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts	15
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results	15
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry	14
Are NOACs always the best strategy in elderly AF patients?	14
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023	14
Photoinduced skin reactions of cardiovascular drugs—a systematic review	14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	13
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis	13
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation	13
Focus on different aspects of atrial fibrillation	13
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	12
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	12
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	12
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	12
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	12
What's new in pharmacotherapy at ESC Congress 2023?	12
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	12
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	11
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	11
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	11
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	11
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	11
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	11
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	11
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	10
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	10
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	10
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	10

Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	10
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	10
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	10
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding	9
FLOW trial stopped early due to evidence of renal protection with semaglutide	9
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	9
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists	9
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis	9
RNA-targeted therapeutics in cardiovascular disease: the time is now	9
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	9
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies	8
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation	8
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?	8
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study	8
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis	8
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?	8
News in cardiovascular pharmacotherapy from the ACC.25 Meeting	8
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study	8
Special focus on the new anti-diabetic drugs	7
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results	7
Future of antithrombotic therapy for heart failure with coronary artery disease	7
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT	7
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?	7
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial	7
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease	7
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation	7
Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study	7
Management of dyslipidaemia in patients with comorbidities: facing the challenge	6
Lipid treatment	6
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2	6
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity	6
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	6
Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RA	6
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19	6
Correction to: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	6
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome	6
Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI	6
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?	6
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure	6
Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI	6
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis	5
The search for the perfect antiplatelet treatment continues	5
Corrigendum to: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	5
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study	5
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis	5
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance	5
LDL lowering effect of PCSK9 inhibition is reduced in women	5
Pharmacogenetic testing to broaden patient eligibility for mavacamten	5
Our knowledge about atrial fibrillation steadily increases	5
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics	5
The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials	5
The role of cangrelor in acute and high-risk PCI settings	5
New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021	5
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry	5
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial	5
EHJCVP Reviewers 2022	5
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?	5
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	5
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis	4
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?	4
Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention	4
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	4
Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study	4
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry	4
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study	4
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis	4
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention	4
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	4
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD	4
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	4
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study	4
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinic	4
CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction	4
Corrigendum to: Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)	4
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials	4
Optimizing individual heart failure treatment	3
Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants	3
Hypertension in pregnancy—what's new in the 2023 ESH Guidelines for the management of arterial hypertension	3
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?	3

Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis	3
Reply to ‘Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction’	3
Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure	3
Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis	3
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?	3
Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data	3
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?	3
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational	3
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48	3
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy	3
2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?	3
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus	3
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial	3
Sex-related differences in platelet aggregation	3
Bleeding and thrombosis	3
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk	3
Fibrates: one more lost paradise in lipid treatment	3
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide co	3
Reaping the rewards of a simplified dosing regimen	3
Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study	3
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease	3
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19	2
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics	2
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock	2
Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction: reply	2
P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting	2
The revolution in pharmacotherapy: from herbs to pills, moulds, antibodies to genetic tools	2
Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis	2
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation	2
Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy	2
Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)	2
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis	2
Oral anticoagulants and antiplatelet treatment in different settings	2
Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study	2
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events	2
To treat or not to treat	2
Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis	2
Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction	2
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and netwo	2
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases	2
Correction to: Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	2
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials	2
Subcutaneous furosemide in heart failure: a systematic review	2
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA	2
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis	2
Unexplored horizons on sex bias and progression of heart failure with preserved ejection fraction	2
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis	2
Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials	2
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension	2